Acromegaly market seen reaching $5.84 billion by 2030

The acromegaly treatment market is projected to climb from $2.56 billion in 2025 to $5.84 billion by 2030, according to The Business Research Company. Growth is being fueled by rising awareness, more diagnosis, and wider use of advanced therapies and digital care tools.

Why it matters: - The acromegaly market is growing as rare-disease diagnosis improves and treatment options expand. - A larger market points to more demand for specialty endocrine care, imaging, testing and long-term patient management. - The report frames acromegaly as part of a broader shift toward earlier diagnosis and personalized treatment for hormone disorders.

What happened: - The Business Research Company said the acromegaly market will rise from $2.56 billion in 2025 to $3.01 billion in 2026. - The same report projects the market will reach $5.84 billion by 2030, representing an 18.1% CAGR. - The company published a sample report and a full market report with updated forecasts and regional analysis. - The report page includes a free sample and the full market report.

The details: - Acromegaly is a rare endocrine disorder caused by excessive growth hormone secretion from the pituitary gland. - The disorder leads to abnormal enlargement and thickening of bones and tissues, especially in the hands, feet and face. - Left untreated, acromegaly can cause serious physical changes and health complications. - The report cites limited diagnostic tools and a rising prevalence of growth hormone disorders as key growth drivers. - Improved hospital infrastructure and specialty clinics are making diagnosis and treatment more accessible. - Traditional treatment methods and higher awareness of rare endocrine conditions are also supporting market growth. - The report points to advanced somatostatin analogues and broader availability of parenteral therapies as future growth drivers. - Precision medicine strategies, outpatient care and homecare treatment models are gaining traction. - Digital health tools and remote monitoring are improving patient management and outcomes. - The report says around half of acromegaly patients develop insulin resistance or type 2 diabetes because elevated growth hormone affects insulin production. - The report uses diabetes care trends as a wider signal of growing attention to hormonal disease management. - North America led the acromegaly market in 2025. - The report also covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The forecast suggests acromegaly care is moving away from a narrow rare-disease niche toward a more structured, tech-enabled treatment market. - Growth is likely to come not just from more patients, but from better detection, longer treatment duration and more advanced care settings. - The report’s focus on digital health and homecare suggests cost and convenience are becoming part of the care model, not just clinical efficacy.

What's next: - The market will likely be shaped by how quickly advanced therapies reach wider use and how healthcare systems improve diagnosis rates. - Regional growth will depend on specialty access, reimbursement and adoption of remote monitoring tools. - The 2026 report edition adds market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, hotspot infographics and updated trend graphics.

The bottom line: - The acromegaly market is on track for fast expansion through 2030, driven by better diagnosis, more treatment options and broader adoption of precision and digital care.